Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxel-cisplatin combination chemotherapy: single institution experience


KOCAK M., MAYADAGLI A., OZKAN A., PARLAK C., DEMIR O., MARTI A., ...More

JOURNAL OF BUON, vol.12, no.4, pp.471-476, 2007 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 4
  • Publication Date: 2007
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.471-476

Abstract

Purpose: Despite advances in the detection and treatment, the long-term survival of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%. We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naive patients with metastatic NSCLC.